Prognosis of Patients with Transected Melanomas
- 1 April 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Dermatologic Surgery
- Vol. 39 (4), 605-615
- https://doi.org/10.1111/dsu.12124
Abstract
Background The management of melanoma is directly related to Breslow's depth. Biopsying melanomas in a fashion that transects the deep margin precludes an accurate measurement of the true depth. Objective To examine the prognosis of melanomas transected along the deep margins, as well as cases where no residual melanoma was seen on re-excision after transection. Methods Records from a cohort of patients at one institution were examined from 1996 through 2007. Patients were considered to have transected melanomas if tumor cells were present on the deep margin of the biopsy. Overall survival was determined. Results Seven hundred fourteen patients were examined. 171 (24%) of all melanomas were transected. 101(59%) of those lacked tumor cells on re-excision. Patients with transected melanomas were older (OR=1.03, p<.001), and had higher Breslow's depths (OR=1.21, p<.001) than those without transected tumors. Those with no residual melanoma after transection were younger (OR = 0.98, p = .010) and more likely to have no lymph node involvement (OR = 2.23, p = .037). Neither transection (p=.760), nor lack of residual melanoma on re-excision after transection (p=.793) influenced survival. Conclusion A high number of melanomas are transected at diagnosis, many of which lack visible tumor. The original Breslow's depth of transected melanomas without residual tumor on re-excision accurately predicts survival and prognosis.Keywords
This publication has 52 references indexed in Scilit:
- The impact of biopsy technique on upstaging, residual disease, and outcome in cutaneous melanomaThe American Journal of Surgery, 2011
- Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology, 2009
- Non-Radical Diagnostic Biopsies Do Not Negatively Influence Melanoma Patient SurvivalAnnals of Surgical Oncology, 2007
- Completely regressed primary cutaneous malignant melanoma with nodal and/or visceral metastases: A report of 5 cases and assessment of the literature and diagnostic criteriaJournal of the American Academy of Dermatology, 2005
- Biopsy techniques: Diagnosis of melanomaDermatologic Clinics, 2002
- Management of cutaneous malignant melanoma by dermatologists of the American Academy of Dermatology. I. Survey of biopsy practices of pigmented lesions suspected as melanomaJournal of the American Academy of Dermatology, 1995
- Pitfalls of Mohs micrographic surgeryJournal of the American Academy of Dermatology, 1990
- Model Predicting Survival in Stage I Melanoma Based on Tumor ProgressionJNCI Journal of the National Cancer Institute, 1989
- Lethal “Thin” Malignant MelanomaAnnals of Surgery, 1988
- Does biopsy type influence survival in Stage I melanoma?Journal of the American Academy of Dermatology, 1986